Combination therapy to checkmate Glioblastoma: clinical challenges and advances

Ghosh, D., Nandi, S., Bhattacharjee, S. (October 2018) Combination therapy to checkmate Glioblastoma: clinical challenges and advances. Clin Transl Med, 7 (1). p. 33. ISSN 2001-1326 (Print)


Download (1MB) | Preview
DOI: 10.1186/s40169-018-0211-8


Combination therapy is increasingly becoming the cornerstone of current day antitumor therapy. Glioblastoma multiforme is an aggressive brain tumor with a dismal median survival post diagnosis and a high rate of disease recurrence. The poor prognosis can be attributed to unique treatment limitations, which include the infiltrative nature of tumor cells, failure of anti-glioma drugs to cross the blood-brain barrier, tumor heterogeneity and the highly metastatic and angiogenic nature of the tumor making cells resistant to chemotherapy. Combination therapy approach is being developed against glioblastoma with new innovative combination drug regimens being tested in preclinical and clinical trials. In this review, we discuss the pathophysiology of glioblastoma, diagnostic markers, therapeutic targeting strategies, current treatment limitations, novel combination therapies in the context of current treatment options and the ongoing clinical trials for glioblastoma therapy.

Item Type: Paper
Subjects: diseases & disorders > cancer > cancer types > glioblastoma
CSHL Authors:
Communities: CSHL labs > Lee lab
CSHL labs > Martienssen lab
CSHL labs > Stillman lab
Depositing User: Matthew Dunn
Date: 16 October 2018
Date Deposited: 01 Nov 2018 18:34
Last Modified: 01 Nov 2018 18:34
PMCID: PMC6191404
Related URLs:

Actions (login required)

Administrator's edit/view item Administrator's edit/view item
CSHL HomeAbout CSHLResearchEducationNews & FeaturesCampus & Public EventsCareersGiving